Physician profile
Jacob Leroux
NPI 1740721745
$626.45
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.45 · 2020: $28.28 · 2021: $371 · 2022: $171.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $206.22 | 2021 | |
| Pfizer INC. | $140.12 | 2020-2021 | |
| Shockwave Medical, INC | $87.88 | 2022 | |
| Novo Nordisk INC | $48.15 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $34.94 | 2021 | |
| Boston Scientific Corporation | $32.61 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $23.20 | 2019 | |
| Genzyme Corporation | $22.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.97 | 2019 | |
| Glaxosmithkline, LLC. | $12.90 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Leroux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.